Iroko Pharmaceuticals Reports Encouraging Results from Study of Naproxen Formulated Using a Proprietary, Patented, Nanotechnology Platform

January 6, 2011 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

(BUSINESS WIRE)--Iroko Pharmaceuticals, LLC today reported the results of the Phase I clinical study of its unique formulation of naproxen, a widely used pain medication, using proprietary, patent protected nanotechnology.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase 1